https://clinicaltrials.gov/ct2/show/NCT03986944?type=Intr
https://clinicaltrials.gov/ct2/show/NCT03986944?type=Intr&cond=Endometriosis&lupd_s=04%2F17%2F2020&lupd_d=14
Condition : Endometriosis
Interventions : Drug: 75 mg linzagolix tablet; Drug: 200 mg linzagolix tablet; Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg); Drug: Placebo tablet to match 75 mg linzagolix tablet; Drug: Placebo tablet to match 200 mg linzagolix tablet; Drug: Placebo capsule to match Add-back capsule
Sponsor : ObsEva SA
Recruiting
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
NCT03986944
Fri, 14 Jun 2019 12:00:00 EDT
Last Update Posted: 05/01/20 08:08AM